These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28363581)

  • 1. The Effect of Triglyceride Concentration on Attainment of Lipid Targets in Patients with Diabetes.
    Cartier LJ; Collins C; Lagacé M; Douville P
    Can J Diabetes; 2017 Aug; 41(4):380-384. PubMed ID: 28363581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.
    Guyton JR; Betteridge DJ; Farnier M; Leiter LA; Lin J; Shah A; Johnson-Levonas AO; Brudi P
    Diab Vasc Dis Res; 2011 Apr; 8(2):160-72. PubMed ID: 21562068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
    Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
    Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reference intervals for six lipid analytes in 8-14 year-old school children from three different ethnical groups in the Hulun Buir area of China.
    Du Y; Sun H; Li Y; Shi X; Pei D; Qi D; Wang B
    Clin Lab; 2014; 60(8):1295-300. PubMed ID: 25185414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios.
    Diaf M; Khaled BM; Sellam F
    Libyan J Med; 2015; 10(1):27400. PubMed ID: 25959906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects.
    De Michele G; Correale M; De Michele O; Guerra V; Mazzarelli R; Misciagna G
    Immunopharmacol Immunotoxicol; 2008; 30(4):925-36. PubMed ID: 18720163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital.
    Cartier LJ; Collins C; Lagacé M; Douville P
    Clin Biochem; 2018 Feb; 52():61-66. PubMed ID: 29129625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
    Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
    Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity.
    Paredes S; Fonseca L; Ribeiro L; Ramos H; Oliveira JC; Palma I
    Sci Rep; 2019 Aug; 9(1):11792. PubMed ID: 31409878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
    Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of several single nucleotide polymorphisms and high body mass index on serum lipid traits.
    Yin RX; Wu DF; Miao L; Htet Aung LH; Cao XL; Yan TT; Long XJ; Liu WY; Zhang L; Li M
    Biofactors; 2013; 39(3):315-25. PubMed ID: 23355348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution and interaction of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross-sectional study.
    Hong M; Ling Y; Lu Z; Liu Y; Gu P; Shao J; Gao X; Li X
    J Diabetes Investig; 2019 Jan; 10(1):131-138. PubMed ID: 29694714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.